Category: CLL
Six-Year Update of the ELEVATE-TN Study on Acalabrutinib
H&O Could you describe the impetus for and design of the ELEVATE-TN trial? JS The ELEVATE-TN study was conducted to seek regulatory authorization for acalabrutinib (Calquence, […]
Genomic Risk Stratification in Chronic Lymphocytic Leukemia
H&O Which patients with chronic lymphocytic leukemia (CLL) require treatment? AW A substantial proportion of patients with CLL can go for decades with no need for […]
Preventing Infectious Complications in Chronic Lymphocytic Leukemia
H&O What causes the elevated risk of infections in patients with chronic lymphocytic leukemia (CLL)? CS Immunologic defects in patients with CLL are caused by the […]
Management of Richter Transformation
H&O How often does chronic lymphocytic leukemia (CLL) transform into aggressive lymphoma? MD Transformation of CLL into aggressive lymphoma, known as Richter transformation (RT), is relatively […]
Managing CLL That Has Progressed After BTK Inhibition
H&O When patients with chronic lymphocytic leukemia (CLL) progress while on Bruton tyrosine kinase (BTK) inhibitor therapy, what is your next therapy of choice? LR Because […]
Is There Still a Role for PI3K Inhibitors in CLL?
H&O What did the DUO trial find regarding the use of duvelisib in previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL)? IWF The […]
Addressing Cardiovascular Complications of BTK Inhibitors
H&O What are the specific cardiovascular complications that are associated with Bruton tyrosine kinase (BTK) inhibitors? JM Many cancer drugs have adverse effects on the heart […]
The Use of Zanubrutinib in Chronic Lymphocytic Leukemia
H&O What makes the various Bruton tyrosine kinase (BTK) inhibitors different from one another? DB A variety of BTK inhibitors have been approved for use in […]
The Clinical Importance of Prognostic Markers in CLL
H&O How has the role of prognostic markers in chronic lymphocytic leukemia (CLL) changed with the transition from standard chemoimmunotherapy drugs to targeted agents? JA Since […]
Clinical Use of Measurable Residual Disease in CLL
H&O What are some of the limitations of the International Workshop on CLL (iwCLL) response criteria for chronic lymphocytic leukemia (CLL) in the era of novel […]
The Use of Chimeric Antigen T-Cell Therapy in Chronic Lymphocytic Leukemia
H&O What options are available for patients with chronic lymphocytic leukemia (CLL) that is refractory to Bruton tyrosine kinase (BTK) inhibitors and venetoclax? TS This is […]
The Emerging Role of Pirtobrutinib in Chronic Lymphocytic Leukemia
H&O How has the advent of Bruton tyrosine kinase (BTK) inhibitors impacted the treatment of patients with chronic lymphocytic leukemia (CLL)? NL The advent of BTK […]
The Role of Minimal Residual Disease in Chronic Lymphocytic Leukemia
Abstract: Minimal residual disease (MRD) has evolved as a sensitive and highly prognostic surrogate parameter of response to therapy in chronic lymphocytic leukemia (CLL). Multiple methods […]
Lessons Learned From the CAPTIVATE Trial of Ibrutinib Plus Venetoclax in CLL
H&O Could you describe the design of the CAPTIVATE trial? SO CAPTIVATE is a phase 2 trial in patients with previously untreated chronic lymphocytic leukemia (CLL) […]
Should Venetoclax Be Used With or Without Anti-CD20 Therapy for CLL?
H&O Which patients with chronic lymphocytic leukemia (CLL) are eligible for treatment with venetoclax? RF Nearly all patients with CLL are eligible for treatment with venetoclax […]
Early Intervention in Asymptomatic Chronic Lymphocytic Leukemia
Abstract: Of the estimated 21,000 patients who will receive a new diagnosis of chronic lymphocytic leukemia (CLL) this year in the United States, approximately 80% will […]
CLL In Focus
CLL Linked to Elevated Risk for Second Cancers Even With BTK Inhibition Patients with chronic lymphocytic leukemia (CLL) are at increased risk for second cancers even […]
Highlights in Chronic Lymphocytic Leukemia From the 2020 American Society of Clinical Oncology Annual Meeting
May 29-31, 2020 • Virtual Venetoclax/Obinutuzumab Continues to Demonstrate Superior Efficacy Long-term results from the CLL14 trial continue to show that fixed-duration venetoclax/obinutuzumab (VenG) continues […]
CLL in Focus
Watch and Wait Remains Best Approach for High-Risk Binet Stage A Chronic Lymphocytic Leukemia The current standard of care for patients with Binet stage A chronic […]
CLL In Focus
Complete Response Linked to Progression-Free Survival in Chronic Lymphocytic Leukemia Progression-free survival (PFS) is longer in patients with chronic lymphocytic leukemia (CLL) who have a complete […]